Improvement in thyroid-specific quality of life following radiofrequency ablation of benign thyroid nodules: A USA study.

Autor: Collins RA; School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX. Electronic address: https://twitter.com/ReaganACollins., McManus C; Section of Endocrine Surgery, Columbia University, New York, NY. Electronic address: https://twitter.com/ktmac862., Kuo EJ; Section of Endocrine Surgery, Columbia University, New York, NY. Electronic address: https://twitter.com/EricJKuoMD., Liou R; Section of Endocrine Surgery, Columbia University, New York, NY., Lee JA; Section of Endocrine Surgery, Columbia University, New York, NY., Kuo JH; Section of Endocrine Surgery, Columbia University, New York, NY. Electronic address: jhk2029@cumc.columbia.edu.
Jazyk: angličtina
Zdroj: Surgery [Surgery] 2025 Jan; Vol. 177, pp. 108823. Date of Electronic Publication: 2024 Oct 09.
DOI: 10.1016/j.surg.2024.06.063
Abstrakt: Background: Radiofrequency ablation is an effective minimally invasive technique for benign thyroid nodules, with European and Asian studies reporting improved quality of life following treatment. We aimed to assess the thyroid-related quality of life of patients with benign thyroid nodules treated with radiofrequency ablation in the United States.
Methods: This is a prospective single-institution study of patients treated with radiofrequency ablation over a 4-year period. Nodule characteristics and Thyroid-Related Patient-Reported Outcome (ThyPRO)-39 scores were assessed at baseline, 3 months post-procedure, and last follow-up (range: 3-12 months). Wilcoxon signed-rank test was used to assess differences in scores before and after radiofrequency ablation with standardized effect size analysis.
Results: A total of 56 patients with 76 nodules were treated. The median volume reduction ratio at 1, 3, 6, and 12 months was 44.9% (interquartile range: 27.3-57.3), 65.2% (53.5-73.1), 69.7% (63.5-81.9), and 79.6% (66.2-88.9), respectively. At 3-month follow-up, significant improvement (P < .05) was observed for goiter symptoms (28.9 vs 10.8), anxiety (30.7 vs 19.3), and appearance (29.9 vs 10.8). At last follow-up, significant improvement (P < .05) was observed for goiter symptoms (28.9 vs 8.9), anxiety (30.7 vs 22.3), appearance (29.9 vs 10.8), and overall quality of life (30.3 vs 11.1). Effect sizes were moderate for appearance (standardized effect size 0.5-0.8) at last follow-up.
Conclusion: In the largest US study to date assessing quality of life following radiofrequency ablation, we observed an expected volume reduction ratio and improvements in thyroid-specific quality of life, particularly in the goiter, anxiety, and appearance domains.
Competing Interests: Conflict of Interest/Disclosures Jennifer H. Kuo is a consultant with Medtronic.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: